ValuEngine upgraded shares of Alliqua BioMedical, Inc. (NASDAQ:ALQA) from a sell rating to a hold rating in a report released on Friday.
A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Alliqua BioMedical from a buy rating to a hold rating in a report on Wednesday, September 20th. HC Wainwright reiterated a buy rating and issued a $15.00 target price on shares of Alliqua BioMedical in a report on Monday, September 18th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $11.25.
Shares of Alliqua BioMedical (NASDAQ ALQA) opened at 2.90 on Friday. Alliqua BioMedical has a 12 month low of $0.34 and a 12 month high of $9.20. The company’s market cap is $145.30 million. The stock has a 50 day moving average of $3.35 and a 200-day moving average of $3.82.
Alliqua BioMedical (NASDAQ:ALQA) last issued its earnings results on Thursday, August 10th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.50. Alliqua BioMedical had a negative return on equity of 107.24% and a negative net margin of 185.30%. The company had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $5.01 million. During the same period last year, the business earned ($2.20) EPS. Alliqua BioMedical’s quarterly revenue was up 23.5% compared to the same quarter last year. On average, analysts forecast that Alliqua BioMedical will post ($0.36) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Alliqua BioMedical, Inc. (ALQA) Lifted to Hold at ValuEngine” was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://transcriptdaily.com/2017/10/09/alliqua-biomedical-inc-alqa-lifted-to-hold-at-valuengine.html.
Large investors have recently modified their holdings of the business. Sabby Management LLC lifted its stake in Alliqua BioMedical by 93.7% during the 1st quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock valued at $1,076,000 after acquiring an additional 1,030,652 shares in the last quarter. Perceptive Advisors LLC lifted its stake in Alliqua BioMedical by 120.3% during the 1st quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock valued at $2,136,000 after acquiring an additional 2,312,000 shares in the last quarter. KCG Holdings Inc. lifted its stake in Alliqua BioMedical by 777.7% during the 1st quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock valued at $265,000 after acquiring an additional 465,256 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Alliqua BioMedical by 54.2% during the 1st quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock valued at $319,000 after acquiring an additional 222,400 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.